Rule2023-04364
Schedules of Controlled Substances: Placement of Brorphine in Schedule I
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 6, 2023
Effective
April 5, 2023
Issuing agencies
Justice DepartmentDrug Enforcement Administration
Abstract
With the issuance of this final order, the Administrator of the Drug Enforcement Administration is permanently placing 1-(1-(1-(4- bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as brorphine), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, in schedule I of the Controlled Substances Act. This scheduling action discharges the United States' obligations under the Single Convention on Narcotic Drugs (1961). This action continues to impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, import, export, engage in research or conduct instructional activities with, or possess), or propose to handle brorphine.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 43 (Monday, March 6, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 43 (Monday, March 6, 2023)]
[Rules and Regulations]
[Pages 13692-13694]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-04364]
[[Page 13692]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA-716]
Schedules of Controlled Substances: Placement of Brorphine in
Schedule I
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Final order.
-----------------------------------------------------------------------
SUMMARY: With the issuance of this final order, the Administrator of
the Drug Enforcement Administration is permanently placing 1-(1-(1-(4-
bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one
(commonly known as brorphine), including its isomers, esters, ethers,
salts, and salts of isomers, esters, and ethers whenever the existence
of such isomers, esters, ethers, and salts is possible within the
specific chemical designation, in schedule I of the Controlled
Substances Act. This scheduling action discharges the United States'
obligations under the Single Convention on Narcotic Drugs (1961). This
action continues to impose the regulatory controls and administrative,
civil, and criminal sanctions applicable to schedule I controlled
substances on persons who handle (manufacture, distribute, import,
export, engage in research or conduct instructional activities with, or
possess), or propose to handle brorphine.
DATES: Effective April 5, 2023.
FOR FURTHER INFORMATION CONTACT: Dr. Terrence L. Boos, Drug and
Chemical Evaluation Section, Diversion Control Division, Drug
Enforcement Administration; Telephone: (571) 362-3249.
SUPPLEMENTARY INFORMATION:
Legal Authority
The United States is a party to the 1961 United Nations Single
Convention on Narcotic Drugs (Single Convention), March 30, 1961, 18
U.S.T. 1407, 570 U.N.T.S. 151, as amended. Article 3, paragraph 7 of
the Single Convention requires that if the Commission on Narcotic Drugs
(Commission) adds a substance to one of the schedules of such
Convention, and the United States receives notification of such
scheduling decision from the Secretary-General of the United Nations
(Secretary-General), the United States, as a signatory Member State, is
obligated to control the substance under its national drug control
legislation. Under 21 U.S.C. 811(d)(1)), of the Controlled Substances
Act (CSA), if control of a substance is required ``by United States
obligations under international treaties, conventions, or protocols in
effect on October 27, 1970,'' the Attorney General must issue an order
controlling such drug under the schedule he deems most appropriate to
carry out such obligations, without regard to the findings required by
21 U.S.C. 811(a) or 812(b), and without regard to the procedures
prescribed by 21 U.S.C. 811(a) and (b). The Attorney General has
delegated scheduling authority under 21 U.S.C. 811 to the Administrator
of the Drug Enforcement Administration (Administrator). 28 CFR 0.100.
Background
On March 1, 2021, Drug Enforcement Administrator (DEA) issued a
temporary scheduling order, placing brorphine [1-(1-(1-(4-
bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-
one] in schedule I of the Controlled Substances Act (CSA). 86 FR 11862.
That order was based on findings by the Acting Administrator of DEA
(Acting Administrator) that the temporary scheduling of this substance
was necessary to avoid an imminent hazard to the public safety; the
order was codified at 21 CFR 1308.11(h)(49).
In November 2021, the Director-General of the World Health
Organization (WHO) notified the Secretary-General of the
recommendation, from the 44th meeting of WHO's Expert Committee on Drug
Dependence, that brorphine be placed in Schedule I of the Single
Convention, as this substance has an opioid mechanism of action and
similarity to drugs that are controlled in Schedule I of the Single
Convention (i.e., brorphine is similar to drugs such as morphine and
fentanyl) and has dependence and abuse potential. On May 27, 2022, the
United States government was informed by the Secretariat of the United
Nations, by letter, that during its 65th session in March 2022, the
Commission voted to place brorphine in Schedule I of the Single
Convention (CND Mar/65/1).
Brorphine
As discussed in the background section, brorphine is temporarily
controlled in schedule I of the CSA upon the Acting Administrator's
finding it poses imminent hazard to the public safety. Brorphine has a
pharmacological profile similar to fentanyl (schedule II) and other
schedule I and II synthetic opioids that act as mu-opioid receptor
agonists. Because of the pharmacological similarities of brorphine to
heroin (schedule I) and fentanyl (schedule II), a potent mu-opioid
agonist, the use of brorphine presents a high risk of abuse and has
negatively affected users and communities. The abuse of brorphine has
been associated with at least 21 fatalities in the United States
between August 2019 and June 2021.<SUP>1 2</SUP> The positive
identification of this substance in many post-mortem cases is a serious
concern to the public safety.
---------------------------------------------------------------------------
\1\ Vohra V, King AM, Jacobs E, Aaron C. Death associated with
brorphine, an emerging novel synthetic opioid. Clin Toxicol (Phila).
2021, 59:851-852.
\2\ Krotulski AJ, x Krotulski AJ, Papsun DM, Noble C, Kacinko
SL, Nelson L, Logan BK. Public Health Alert: The Rise of Brorphine--
A Potent New Synthetic Opioid Identified in the Midwestern United
States. CFSRE--NPS Discovery, 2020.
---------------------------------------------------------------------------
Brorphine on the illicit drug market has been reported in Canada,
Estonia, Germany, Latvia, Sweden, and the United States since April
2019.\3\ Law enforcement reports demonstrate that brorphine is being
illicitly distributed and abused. According to the National Forensic
Laboratory Information System (NFLIS-Drug) database, which collects
drug identification results from drug cases submitted to and analyzed
by Federal, State and local forensic laboratories, there have been 157
reports for brorphine between April 2020 and June 2022 \4\ (query date:
July 6, 2022).
---------------------------------------------------------------------------
\3\ Health Canada Drug Analysis Service (2019); Analyzed Drug
Report Canada 2019--Q3 (July to September); European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) (2020); EU Early
Warning System Situation Report, Situation report--June 2020.
\4\ Reports for NFLIS-Drug are still pending for 2022.
---------------------------------------------------------------------------
DEA is not aware of any claims or any medical or scientific
literature suggesting that brorphine has a currently accepted medical
use in treatment in the United States. In addition, the Department of
Health and Human Services advised DEA, by letter dated October 27,
2020, that there were no investigational new drug applications or
approved new drug applications for brorphine in the United States.
Because brorphine is not formulated or available for clinical use as an
approved medicinal product, all current use of this substance by
individuals is based on their own initiative, rather than on the basis
of medical advice from a practitioner licensed by law to administer
such a drug.
Therefore, consistent with 21 U.S.C. 811(d)(1), DEA concludes that
brorphine has no currently accepted medical use in treatment in the
United States \5\ and
[[Page 13693]]
is most appropriately placed in schedule I of the CSA, the same
schedule in which it currently resides. Because control is required
under the Single Convention, DEA will not be initiating regular
rulemaking proceedings to schedule brorphine pursuant to 21 U.S.C.
811(a).
---------------------------------------------------------------------------
\5\ Although, as discussed above, there is no evidence
suggesting that brorphine has a currently accepted medical use in
treatment in the United States, it bears noting that a drug cannot
be found to have such medical use unless DEA concludes that it
satisfies a five-part test. Specifically, with respect to a drug
that has not been approved by the Food and Drug Administration, to
have a currently accepted medical use in treatment in the United
States, all of the following must be demonstrated: i. the drug's
chemistry must be known and reproducible; ii. there must be adequate
safety studies; iii. there must be adequate and well-controlled
studies proving efficacy; iv. the drug must be accepted by qualified
experts; and v. the scientific evidence must be widely available. 57
FR 10499 (1992), pet. for rev. denied, Alliance for Cannabis
Therapeutics v. DEA, 15 F.3d 1131, 1135 (D.C. Cir. 1994).
---------------------------------------------------------------------------
Conclusion
In order to meet the United States' obligations under the Single
Convention and because brorphine has no currently accepted medical use
in treatment in the United States, the Administrator has determined
that brorphine, including its isomers, esters, ethers, salts, and salts
of isomers, esters, and ethers, whenever the existence of such isomers,
esters, ethers, and salts is possible within the specific chemical
designation, should remain in schedule I of the CSA.
Requirements for Handling
Brorphine has been controlled as a schedule I controlled substance
since March 1, 2021. Upon the effective date of the final order
contained in this document, brorphine will be permanently subject to
the CSA's schedule I regulatory controls and administrative, civil, and
criminal sanctions applicable to the manufacture of, distribution of,
importation of, exportation of, engagement in research or conduct of
instructional activities with, and possession of, schedule I controlled
substances, including the following:
1. Registration. Any person who handles (manufactures, distributes,
imports, exports, engages in research or conducts instructional
activities with, or possesses) or who desires to handle brorphine must
be registered with DEA to conduct such activities pursuant to 21 U.S.C.
822, 823, 957, and 958, and in accordance with 21 CFR parts 1301 and
1312. Retail sales of schedule I controlled substances to the general
public are not allowed under the CSA. Possession of any quantity of
these substances in a manner not authorized by the CSA is unlawful and
those in possession of any quantity of these substances may be subject
to prosecution pursuant to the CSA.
2. Disposal of stocks. Brorphine must be disposed of in accordance
with 21 CFR part 1317, in addition to all other applicable federal,
state, local, and tribal laws.
3. Security. Brorphine is subject to schedule I security
requirements and must be handled and stored pursuant to 21 U.S.C. 823
and in accordance with 21 CFR 1301.71-1301.76. Non-practitioners
handling brorphine must also comply with the employee screening
requirements of 21 CFR 1301.90-1301.93.
4. Labeling and packaging. All labels, labeling, and packaging for
commercial containers of brorphine must be in compliance with 21 U.S.C.
825 and be in accordance with 21 CFR part 1302.
5. Quota. Only registered manufacturers are permitted to
manufacture brorphine in accordance with a quota assigned pursuant to
21 U.S.C. 826 and in accordance with 21 CFR part 1303.
6. Inventory. Every DEA registrant who possesses any quantity of
brorphine has been required to keep an inventory of all stocks of this
substance on hand as of March 1, 2021, pursuant to 21 U.S.C. 827 and in
accordance with 21 CFR 1304.03, 1304.04, and 1304.11.
7. Records and Reports. DEA registrants must maintain records and
submit reports with respect to brorphine pursuant to 21 U.S.C. 827 and
in accordance with 21 CFR 1301.74(b) and (c), 1301.76(b), 1307.11, and
parts 1304, 1312, and 1317. Manufacturers and distributors must submit
reports regarding brorphine to the Automation of Reports and
Consolidated Order System pursuant to 21 U.S.C. 827 and in accordance
with 21 CFR parts 1304 and 1312.
8. Order Forms. All DEA registrants who distribute brorphine must
continue to comply with order form requirements pursuant to 21 U.S.C.
828 and in accordance with 21 CFR part 1305.
9. Importation and Exportation. All importation and exportation of
brorphine must continue to be in compliance with 21 U.S.C. 952, 953,
957, and 958 and in accordance with 21 CFR parts 1304, 1312, and 1317.
10. Liability. Any activity involving brorphine not authorized by,
or in violation of the CSA, is unlawful and may subject the person to
administrative, civil, and/or criminal sanctions.
Regulatory Analyses
Executive Orders 12866 (Regulatory Planning and Review) and 13563
(Improving Regulation and Regulatory Review)
This action is not a significant regulatory action as defined by
Executive Order (E.O.) 12866 Regulatory Planning and Review, section
3(f), and the principles reaffirmed in E.O. 13563 Improving Regulation
and Regulatory Review; and, accordingly, this action has not been
reviewed by the Office of Management and Budget. This action makes no
change in the status quo, as brorphine is already listed as a schedule
I controlled substance.
Executive Order 12988, Civil Justice Reform
This action meets the applicable standards set forth in sections
3(a) and 3(b)(2) of E.O. 12988 to eliminate drafting errors and
ambiguity, minimize litigation, provide a clear legal standard for
affected conduct, and promote simplification and burden reduction.
Executive Order 13132, Federalism
This action does not have federalism implications warranting the
application of E.O. 13132. This action does not have substantial direct
effects on the States, on the relationship between the national
government and the States, or on the distribution of power and
responsibilities among the various levels of government.
Executive Order 13175, Consultation and Coordination With Indian Tribal
Governments
This action does not have tribal implications warranting the
application of E.O. 13175. The action does not have substantial direct
effects on one or more Indian tribes, on the relationship between the
Federal government and Indian tribes, or on the distribution of power
and responsibilities between the Federal government and Indian tribes.
Administrative Procedure Act
The CSA provides for an expedited scheduling action where control
is required by the United States' obligations under international
treaties, conventions, or protocols. 21 U.S.C. 811(d)(1). If control is
required pursuant to such international treaty, convention, or
protocol, the Attorney General, as delegated to the Administrator, must
issue an order controlling such drug under the schedule he deems most
appropriate to carry out such obligations, and ``without regard to''
the findings and rulemaking procedures
[[Page 13694]]
otherwise required for scheduling actions in 21 U.S.C. 811(a) and (b).
In accordance with 21 U.S.C. 811(d)(1), scheduling actions for
drugs that are required to be controlled by the United States'
obligations under international treaties, conventions, or protocols in
effect on October 27, 1970 shall be issued by order (as opposed to
scheduling by rule pursuant to 21 U.S.C. 811(a)). Therefore, DEA
believes that the notice and comment requirements of section 553 of the
Administrative Procedure Act (APA), 5 U.S.C. 553, do not apply to this
scheduling action.
Regulatory Flexibility Act
The Regulatory Flexibility Act (RFA) (5 U.S.C. 601-612) applies to
rules that are subject to notice and comment under section 553(b) of
the APA or any other law. As explained above, the CSA exempts this
final order from notice and comment. Consequently, the RFA does not
apply to this action.
Unfunded Mandates Reform Act of 1995
In accordance with the Unfunded Mandates Reform Act (UMRA) of 1995,
2 U.S.C. 1501 et seq., DEA has determined and certifies that this
action would not result in any Federal mandate that may result ``in the
expenditure by State, local, and tribal governments, in the aggregate,
or by the private sector, of $100,000,000 or more (adjusted annually
for inflation) in any 1 year * * *.'' Therefore, neither a Small
Government Agency Plan nor any other action is required under UMRA of
1995.
Congressional Review Act
This order is not a major rule as defined by the Congressional
Review Act (CRA), 5 U.S.C. 804. However, pursuant to the CRA, DEA is
submitting a copy of this final rule to both Houses of Congress and to
the Comptroller General.
List of Subjects in 21 CFR Part 1308
Administrative practice and procedure, Drug traffic control,
Reporting and recordkeeping requirements.
For the reasons set out above, DEA amends 21 CFR part 1308 as
follows:
PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES
0
1. The authority citation for part 1308 continues to read as follows:
Authority: 21 U.S.C. 811, 812, 871(b), 956(b), unless otherwise
noted.
0
2. In Sec. 1308.11:
0
a. Redesignate paragraphs (b)(22) through (93) as paragraphs (b)(23)
through (94), respectively;
0
b. Add new paragraph (b)(22); and
0
c. Remove and reserve paragraph (h)(49).
The addition reads as follows:
Sec. 1308.11 Schedule I.
* * * * *
(b) * * *
(22) brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)- 9098
1,3-dihydro-2H-benzo[d]imidazol-2-one)........................
* * * * *
Signing Authority
This document of the Drug Enforcement Administration was signed on
February 27, 2023, by Administrator Anne Milgram. That document with
the original signature and date is maintained by DEA. For
administrative purposes only, and in compliance with requirements of
the Office of the Federal Register, the undersigned DEA Federal
Register Liaison Officer has been authorized to sign and submit the
document in electronic format for publication, as an official document
of DEA. This administrative process in no way alters the legal effect
of this document upon publication in the Federal Register.
Scott Brinks,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2023-04364 Filed 3-3-23; 8:45 am]
BILLING CODE 4410-09-P
</pre></body>
</html>Indexed from Federal Register on March 6, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.